- Home
- FLNC vs TYRA Comparison
FLNC vs TYRA Comparison
Compare FLNC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- TYRA
- Stock Information
- Founded
- FLNC 2018
- TYRA 2018
- Country
- FLNC United States
- TYRA United States
- Employees
- FLNC N/A
- TYRA N/A
- Industry
- FLNC Industrial Machinery/Components
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- FLNC Miscellaneous
- TYRA Health Care
- Exchange
- FLNC Nasdaq
- TYRA Nasdaq
- Market Cap
- FLNC 974.7M
- TYRA 844.2M
- IPO Year
- FLNC 2021
- TYRA 2021
- Fundamental
- Price
- FLNC $20.80
- TYRA $15.43
- Analyst Decision
- FLNC Hold
- TYRA Strong Buy
- Analyst Count
- FLNC 19
- TYRA 5
- Target Price
- FLNC $9.86
- TYRA $31.20
- AVG Volume (30 Days)
- FLNC 8.7M
- TYRA 232.5K
- Earning Date
- FLNC 11-24-2025
- TYRA 11-14-2025
- Dividend Yield
- FLNC N/A
- TYRA N/A
- EPS Growth
- FLNC N/A
- TYRA N/A
- EPS
- FLNC N/A
- TYRA N/A
- Revenue
- FLNC $2,449,087,000.00
- TYRA N/A
- Revenue This Year
- FLNC N/A
- TYRA N/A
- Revenue Next Year
- FLNC $20.52
- TYRA N/A
- P/E Ratio
- FLNC N/A
- TYRA N/A
- Revenue Growth
- FLNC 14.26
- TYRA N/A
- 52 Week Low
- FLNC $3.46
- TYRA $6.42
- 52 Week High
- FLNC $24.00
- TYRA $17.78
- Technical
- Relative Strength Index (RSI)
- FLNC 64.46
- TYRA 61.25
- Support Level
- FLNC $17.90
- TYRA $13.75
- Resistance Level
- FLNC $20.18
- TYRA $16.05
- Average True Range (ATR)
- FLNC 1.97
- TYRA 0.84
- MACD
- FLNC 0.09
- TYRA 0.05
- Stochastic Oscillator
- FLNC 79.83
- TYRA 73.04
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.